Saturday 17 October 2026
Export INDV’s income statement to Excel — free account
Indivior Pharmaceuticals Inc.
INDV Healthcare Drug Manufacturers Specialty & Generic
Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024. In the quarter to June 2026, revenue grew 13.6%, EPS grew 580.0%, free cash flow grew 58.6% and total debt rose 49.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
32.45
1.17
−3.48%
Follow INDV
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | 5 | 4 | 7 |
+8 more TTM periods Free account |
| (153.12%) | (117.21%) | (96.33%) | (68.45%) | ||
| 26.52% | 19.60% | 16.69% | 8.89% | ||
ROIC |
460.53% | 124.25% | 629.81% | 0.00% | |
Return on Tangible Assets |
1,873.68% | 560.00% | (177.97%) | 158.02% | |
Average Days of Receivables |
78.70 | 80.64 | 75.12 | 84.14 | |
Free Cash Flow per Share |
(0.93) | (1.55) | (0.76) | 0.94 | |
Free Cash Flow |
(111.00) | (192.00) | (95.00) | 117.00 | |
Capital Expenditures |
(71.00) | (81.00) | (68.00) | (60.00) | |
| Other line items | |||||
Cash ROIC |
(22.16%) | (37.14%) | (22.84%) | 20.89% | |
Accounts Receivable Turnover |
5.02 | 4.63 | 4.57 | 4.35 | |
Accounts Payable Turnover |
1.19 | 1.34 | 1.06 | 0.44 | |
Inventory Turnover |
1.61 | 1.54 | 1.54 | 1.36 | |
Average Days of Payables |
313.29 | 268.47 | 370.94 | 345.70 | |
Days of Inventory on Hand |
228.13 | 229.26 | 227.01 | 249.23 | |
Tax Rate |
(0.10) | (0.15) | (0.12) | (0.34) | |
Research and Development Expense of Revenue |
6.16% | 7.05% | 7.83% | 9.07% | |
Selling, General and Administrative Expense of Revenue |
44.25% | 48.45% | 51.17% | 52.63% | |
Share Based Compensation of Revenue |
2.40% | 2.25% | 2.10% | 2.29% | |
Interest Coverage |
15.56 | 8.30 | 5.82 | 4.45 | |
Operating CF/Net income |
(0.11) | (0.44) | (0.13) | 1.38 | |
Depreciation/Fixed assets |
0.10 | 0.12 | 0.14 | 0.19 | |
Capex/Depreciation |
(4.18) | (4.26) | (3.40) | (2.50) | |
Revenue per Share |
11.18 | 10.40 | 9.91 | 9.44 | |
Operating CF per Share |
(0.34) | (0.90) | (0.22) | 1.42 | |
Capex per Share |
(0.60) | (0.65) | (0.54) | (0.48) | |
Capex to Sales |
0.05 | 0.06 | 0.05 | 0.05 |
Columns are period end dates · fundamentals updated 2 Oct 2026